ElaC Homolog 2 (ELAC2) (N-Term) Peptid
ELAC2
Reaktivität: Human
Wirt: Synthetic
BP, WB
-
- Target Alle ELAC2 Produkte
- ELAC2 (ElaC Homolog 2 (ELAC2))
- Protein Region
- N-Term
- Spezies
- Human
-
Quelle
- Synthetic
- Applikation
- Blocking Peptide (BP), Western Blotting (WB)
- Sequenz
- LLRSAAGRTM SQGRTISQAP ARRERPRKDP LRHLRTREKR GPSGCSGGPN
- Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti- ELAC2 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- ELAC2 (ElaC Homolog 2 (ELAC2))
- Hintergrund
-
The protein encoded by this gene has a C-terminal domain with tRNA 3′, processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
Alias Symbols: ELC2, HPC2, COXPD17
Protein Size: 786 - Gen-ID
- 60528
- NCBI Accession
- NM_001165962, NP_001159434
-
Sie sind hier:
